Shares of Evoke Pharma, Inc. (NASDAQ:EVOK) have received an average rating of “Hold” from the seven research firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $8.20.
EVOK has been the topic of several research reports. FBR & Co reaffirmed a “buy” rating and set a $9.00 price target on shares of Evoke Pharma in a report on Thursday, May 18th. ValuEngine lowered shares of Evoke Pharma from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price target on shares of Evoke Pharma in a report on Tuesday, August 15th. Finally, Zacks Investment Research lowered shares of Evoke Pharma from a “hold” rating to a “sell” rating in a report on Thursday, August 17th.
Evoke Pharma (EVOK) traded up 1.62% during trading on Tuesday, hitting $2.51. The stock had a trading volume of 19,441 shares. The stock’s market capitalization is $38.62 million. Evoke Pharma has a 52-week low of $1.35 and a 52-week high of $4.55. The stock’s 50-day moving average is $2.43 and its 200-day moving average is $2.71.
Evoke Pharma (NASDAQ:EVOK) last announced its quarterly earnings results on Monday, August 14th. The specialty pharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.15. During the same quarter in the prior year, the company earned ($0.41) EPS. On average, analysts predict that Evoke Pharma will post ($0.88) earnings per share for the current fiscal year.
Large investors have recently bought and sold shares of the company. State Treasurer State of Michigan raised its stake in Evoke Pharma by 62.2% in the first quarter. State Treasurer State of Michigan now owns 291,966 shares of the specialty pharmaceutical company’s stock worth $905,000 after buying an additional 111,966 shares during the last quarter. Vanguard Group Inc. raised its stake in Evoke Pharma by 15.1% in the second quarter. Vanguard Group Inc. now owns 523,650 shares of the specialty pharmaceutical company’s stock worth $1,341,000 after buying an additional 68,544 shares during the last quarter. Finally, Sphera Funds Management LTD. acquired a new stake in Evoke Pharma during the first quarter worth $1,550,000. 12.37% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This piece of content was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://stocknewstimes.com/2017/08/27/evoke-pharma-inc-evok-given-consensus-recommendation-of-hold-by-brokerages.html.
About Evoke Pharma
Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
Receive News & Ratings for Evoke Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
